Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | LPL | P06858 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047372 | 0.86 | THRB (0.50) | THRBALDH1A1CA2KMT2APLK1 | |
| SCHEMBL2089568 | 0.83 | ESR1 (0.57) | THRBLPLLIPGALDH1A1KMT2A | |
| SCHEMBL21633839 | 0.83 | ESR1 (0.57) | THRBLPLLIPGALDH1A1KMT2A | |
| SCHEMBL970450 | 0.80 | SMN1; SMN2 (0.45) | LPLLIPGALDH1A1CA2RAB9A | |
| SCHEMBL2202805 | 0.80 | THRB (0.52) | THRBLPLLIPGALDH1A1CA2 | |
| SCHEMBL9218600 | 0.80 | THRB (0.52) | THRBLPLLIPGALDH1A1CA2 | |
| SCHEMBL142480 | 0.79 | LPL (0.62) | THRBLPLLIPGALDH1A1CA2 | |
| SCHEMBL91277 | 0.78 | TAAR1 (0.64) | CA2TAAR1 | |
| SCHEMBL11490631 | 0.77 | NR3C1 (0.44) | ALDH1A1RAB9ATAAR1 | |
| SCHEMBL21633649 | 0.76 | LPL (0.45) | THRBLPLLIPGALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315828-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-09-29 | — | — | CN | disclosed |
| CN-112154167-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-08-22 | — | — | CN | disclosed |
| CN-107918247-B | Colored curable resin composition | 住友化学株式会社 | 2022-03-18 | — | — | CN | disclosed |
| CN-106019840-B | Colored curable resin composition | 东友精细化工有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| CN-111315828-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-06-19 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-4165315-A | CHLORINATION WITH AN N-CHLORO HALOGENATING AGENT | ELI LILLY AND COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4159272-A | Process for 2-chlorosulfinylazetidin-4-ones | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4115383-A | Alkoxycarbonyl-ethylthio-azetidinones and process for their preparation | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4081440-A | Sulfinyl halides and their preparation from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4075203-A | Process for preparing a 3-exomethylenecepham sulfoxide from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4048162-A | Process for preparing 3-hydroxy cephalosporins | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4031082-A | Process for preparing 3-acycloxymethyl-2-cephem compounds | ELI LILLY AND COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-4029651-A | ESTERIFICATION | ELI LILLY AND COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4008230-A | Process for preparing 3-hydroxy cephalosporins | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-4008231-A | Preparation of 3-methoxymethylcephalosporins | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | THRB 758/4885LPL 4835/4885LIPG 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.